Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherRevenue (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Design Therapeutics (DSGN) Shares Outstanding (2020 - 2026)

Design Therapeutics' Shares Outstanding history spans 2 years, with the latest figure at $55.4 million for Q4 2021.

  • On a quarterly basis, Shares Outstanding rose 247.43% to $55.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was $55.4 million, a 247.43% increase, with the full-year FY2021 number at $55.4 million, up 247.43% from a year prior.
  • Shares Outstanding hit $55.4 million in Q4 2021 for Design Therapeutics, roughly flat from $55.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for DSGN hit a ceiling of $55.4 million in Q4 2021 and a floor of $15.7 million in Q1 2020.